argenex (NASDAQ:ARGX) Price Target Raised to $861.00

by · The Cerbat Gem

argenex (NASDAQ:ARGX – Free Report) had its price target raised by Robert W. Baird from $823.00 to $861.00 in a research report sent to investors on Friday,Benzinga reports. Robert W. Baird currently has a neutral rating on the stock.

Several other equities research analysts also recently commented on ARGX. Royal Bank Of Canada decreased their target price on shares of argenex from $1,100.00 to $1,025.00 and set an “outperform” rating for the company in a research report on Tuesday, October 20th. UBS Group upgraded argenex from a “neutral” rating to a “buy” rating and lifted their price target for the company from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. HC Wainwright upped their price target on argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Oppenheimer lowered their price target on argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a research report on Monday, October 12th. Finally, Barclays restated a “buy” rating on shares of argenex in a research note on Monday, September 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,142.37.

Check Out Our Latest Research Report on ARGX

argenex Stock Performance

Shares of ARGX stock opened at $873.71 on Friday. The firm has a market capitalization of $54.95 billion, a PE ratio of 30.49, a price-to-earnings-growth ratio of 0.89 and a beta of 0.44. The firm has a fifty day simple moving average of $956.62 and a two-hundred day simple moving average of $886.34. argenex has a 12 month low of $661.85 and a 12 month high of $1,072.75.

argenex (NASDAQ:ARGX – Get Free Report) last released its quarterly earnings data on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, topping the consensus estimate of $7.44 by $0.36. argenex had a net margin of 31.66% and a return on equity of 47.70%. The firm had revenue of $1.75 billion for the quarter. On average, equities analysts predict that argenex will post 25.79 earnings per share for the current fiscal year.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently modified their holdings of the business. Sigma Planning Corp bought a new position in argenex in the 3rd quarter valued at $1,027,000. Signaturefd LLC grew its position in argenex by 2.6% during the third quarter. Signaturefd LLC now owns 2,129 shares of the company’s stock valued at $2,041,000 after buying an additional 54 shares during the period. BG Investment Services LLC purchased a new stake in argenex during the third quarter worth about $1,397,000. Sowell Financial Services LLC increased its holdings in argenex by 25.8% during the third quarter. Sowell Financial Services LLC now owns 459 shares of the company’s stock worth $440,000 after buying an additional 94 shares during the last quarter. Finally, Guardian Partners Inc. bought a new stake in argenex in the third quarter worth about $863,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Key argenex News

Here are the key news stories impacting argenex this week:

  • Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
  • Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
  • Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
  • Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

About argenex

(Get Free Report)

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.

Featured Articles